Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368757 | 0.74 | LMNA (0.47) | LMNAPOLBPKM | |
| SCHEMBL17334725 | 0.72 | HTT (0.30) | PIP4K2C | |
| SCHEMBL5791703 | 0.71 | CCR1 (0.42) | LMNAGAA | |
| SCHEMBL2369061 | 0.69 | FGFR1 (0.50) | LMNA | |
| SCHEMBL6364094 | 0.68 | LIMK1 (0.43) | MRGPRX1LMNA | |
| SCHEMBL5926294 | 0.68 | MAPK1 (0.41) | PKM | |
| SCHEMBL5788742 | 0.68 | MAPT (0.56) | LMNAPOLBPIP4K2C | |
| SCHEMBL2369510 | 0.67 | SMN1; SMN2 (0.52) | LMNAPIP4K2C | |
| SCHEMBL2369951 | 0.65 | SMN1; SMN2 (0.39) | LMNAPOLBGAAPKM | |
| SCHEMBL5790076 | 0.64 | SMN1; SMN2 (0.37) | LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155194-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-103459384-A | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS INC | 2013-12-18 | — | — | CN | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-20060063818-A1 | Hydantoin derivatives and deren verwendung als tace inhibitoren | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | US | disclosed |
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ASTAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1539740-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539159-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | IRAK4 1189/4885MRGPRX1 1253/4885LMNA 2593/4885 |
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ADAM10, ADAM17, TNF | IRAK4 796/4885MRGPRX1 2007/4885LMNA 2017/4885 |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | MMP1, TPSAB1, CASP1 | IRAK4 251/4885MRGPRX1 1234/4885LMNA 4174/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | IRAK4 1204/4885MRGPRX1 1176/4885LMNA 2817/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | IRAK4 962/4885MRGPRX1 1211/4885LMNA 2157/4885 |
| US-20060063818-A1 | Hydantoin derivatives and deren verwendung als tace inhibitoren | HPN, ADAM17, ADAM33 | IRAK4 1220/4885MRGPRX1 3581/4885LMNA 939/4885 |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | IRAK4 2860/4885MRGPRX1 902/4885LMNA 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.